Ranbaxy Laboratories’ Q1 consolidated net declines by 21%

05 Aug 2011 Evaluate

The Company showcasing a turnaround for the quarter has reported net profit at Rs 150.37 crore as compared to net loss of Rs 7.7 lakh for the quarter ended June 30, 2010 has reported results for the quarter ended June 30, 2011. Its total income has surged by 8.14% at Rs 1326.76 crore for the quarter under review from Rs 1226.86 crore for the corresponding quarter of the previous year.

On Consolidated basis, the Group ‘s profit after tax and minority interest has declined by 21.32% at Rs 243.23 crore for the quarter from Rs 325.71 crore for the corresponding quarter of the previous Fiscal. Its total Income has decreased by 4.31% at Rs 2172.26 crore for Q1FY12 from Rs 2270.07 crore for the Q1FY11.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has its R & D centre that helps company to have long term competive advantage.It caters treatment to segment of diseases that includes Cardiovasculars, Central Nervous System, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology.

Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1272.70
Cipla 1498.90
Zydus Lifesciences 920.90
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×